Literature DB >> 19858384

Bladder cancer: narrowing the gap between evidence and practice.

Maha H A Hussain1, David P Wood, Dean F Bajorin, Bernard H Bochner, Robert Dreicer, Donald L Lamm, Michael A O'Donnell, Arlene O Siefker-Radtke, Dan Theodorescu, Colin P Dinney.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19858384      PMCID： PMC4659855          DOI： 10.1200/JCO.2009.23.6901

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  50 in total

1.  Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2.

Authors:  Amir Sherif; Erkki Rintala; Oddvar Mestad; Jonas Nilsson; Lars Holmberg; Sten Nilsson; Per-Uno Malmström
Journal:  Scand J Urol Nephrol       Date:  2002

2.  Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.

Authors:  Martin G Friedrich; Uwe Pichlmeier; Hartwig Schwaibold; Stefan Conrad; Hartwig Huland
Journal:  Eur Urol       Date:  2007-03-12       Impact factor: 20.096

3.  Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion.

Authors:  Patrik Andius; Sonny L Johansson; Sten Holmäng
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

4.  Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.

Authors:  R Millikan; C Dinney; D Swanson; P Sweeney; J Y Ro; T L Smith; D Williams; C Logothetis
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

5.  Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

Authors:  Guido Dalbagni; Paul Russo; Joel Sheinfeld; Madhu Mazumdar; William Tong; Farhang Rabbani; Machelle S Donat; Harry W Herr; Pramod Sogani; Dominique dePalma; Dean Bajorin
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

6.  Superficial bladder cancer: progression and recurrence.

Authors:  N M Heney; S Ahmed; M J Flanagan; W Frable; M P Corder; M D Hafermann; I R Hawkins
Journal:  J Urol       Date:  1983-12       Impact factor: 7.450

7.  Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.

Authors:  J A Witjes; C T Caris; N A Mungan; F M Debruyne; W P Witjes
Journal:  J Urol       Date:  1998-11       Impact factor: 7.450

8.  Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study.

Authors:  Eero Kaasinen; Hans Wijkström; Per Uno Malmström; Sverker Hellsten; Milos Duchek; Oddvar Mestad; Erkki Rintala
Journal:  Eur Urol       Date:  2003-06       Impact factor: 20.096

9.  Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder.

Authors:  A G van der Heijden; L A Kiemeney; O N Gofrit; O Nativ; A Sidi; Z Leib; R Colombo; R Naspro; M Pavone; J Baniel; F Hasner; J A Witjes
Journal:  Eur Urol       Date:  2004-07       Impact factor: 20.096

10.  Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group.

Authors:  P U Malmström; E Rintala; R Wahlqvist; P Hellström; S Hellsten; E Hannisdal
Journal:  J Urol       Date:  1996-06       Impact factor: 7.450
View more
  20 in total

Review 1.  Muscle-invasive urothelial bladder cancer: an update on systemic therapy.

Authors:  Hayley Knollman; J Luke Godwin; Rishi Jain; Yu-Ning Wong; Elizabeth R Plimack; Daniel M Geynisman
Journal:  Ther Adv Urol       Date:  2015-12

Review 2.  Neoadjuvant chemotherapy for invasive bladder cancer.

Authors:  Guru Sonpavde; Cora N Sternberg
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

3.  Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer.

Authors:  Heiko Schöder; Seng C Ong; Victor E Reuter; Shangde Cai; Eva Burnazi; Guido Dalbagni; Steven M Larson; Bernard H Bochner
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

Review 4.  Biomarkers for prognosis and treatment selection in advanced bladder cancer patients.

Authors:  Yuanbin Ru; Garrett M Dancik; Dan Theodorescu
Journal:  Curr Opin Urol       Date:  2011-09       Impact factor: 2.309

5.  MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

Authors:  Andreas-Claudius Hoffmann; Peter Wild; Christina Leicht; Simone Bertz; Kathleen D Danenberg; Peter V Danenberg; Robert Stöhr; Michael Stöckle; Jan Lehmann; Martin Schuler; Arndt Hartmann
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

6.  The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis.

Authors:  Min Yang; Mihaela V Georgieva; Iryna Bocharova; Mohini Vembusubramanian; Kun Qian; Amy Guo; Ashish M Kamat
Journal:  Adv Ther       Date:  2021-01-11       Impact factor: 3.845

7.  A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.

Authors:  Steven Christopher Smith; Alexander Spyridon Baras; Garrett Dancik; Yuanbin Ru; Kuan-Fu Ding; Christopher A Moskaluk; Yves Fradet; Jan Lehmann; Michael Stöckle; Arndt Hartmann; Jae K Lee; Dan Theodorescu
Journal:  Lancet Oncol       Date:  2011-01-20       Impact factor: 41.316

8.  NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

Authors:  Peter E Clark; Philippe E Spiess; Neeraj Agarwal; Rick Bangs; Stephen A Boorjian; Mark K Buyyounouski; Jason A Efstathiou; Thomas W Flaig; Terence Friedlander; Richard E Greenberg; Khurshid A Guru; Noah Hahn; Harry W Herr; Christopher Hoimes; Brant A Inman; A Karim Kader; Adam S Kibel; Timothy M Kuzel; Subodh M Lele; Joshua J Meeks; Jeff Michalski; Jeffrey S Montgomery; Lance C Pagliaro; Sumanta K Pal; Anthony Patterson; Daniel Petrylak; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Wade J Sexton; Arlene O Siefker-Radtke; Guru Sonpavde; Jonathan Tward; Geoffrey Wile; Mary A Dwyer; Courtney Smith
Journal:  J Natl Compr Canc Netw       Date:  2016-10       Impact factor: 11.908

9.  Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours.

Authors:  José Alexandre Ferreira; Paula A Videira; Luís Lima; Sofia Pereira; Mariana Silva; Mylène Carrascal; Paulo F Severino; Elisabete Fernandes; Andreia Almeida; Céu Costa; Rui Vitorino; Teresina Amaro; Maria J Oliveira; Celso A Reis; Fabio Dall'Olio; Francisco Amado; Lúcio Lara Santos
Journal:  Mol Oncol       Date:  2013-03-21       Impact factor: 6.603

10.  Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.

Authors:  Noura J Choudhury; Alexa Campanile; Tatjana Antic; Kai Lee Yap; Carrie A Fitzpatrick; James L Wade; Theodore Karrison; Walter M Stadler; Yusuke Nakamura; Peter H O'Donnell
Journal:  J Clin Oncol       Date:  2016-04-04       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.